Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal

An Bras Dermatol. 2022 Nov-Dec;97(6):816-819. doi: 10.1016/j.abd.2021.12.004. Epub 2022 Sep 10.

Authors

José Miguel Neves¹, Nélia Cunha², André Lencastre², Joana Cabete²

Affiliations

¹ Department of Dermatology and Venereology, Hospital de Santo António dos Capuchos, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal. Electronic address: [email protected].
² Department of Dermatology and Venereology, Hospital de Santo António dos Capuchos, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.

No abstract available

MeSH terms

Adalimumab / therapeutic use
Anti-Inflammatory Agents / therapeutic use
Hidradenitis Suppurativa* / drug therapy
Humans
Portugal
Severity of Illness Index
Tertiary Care Centers

Substances

Anti-Inflammatory Agents
Adalimumab